Advances in ex vivo mRNA-based gene transfer for cell-based cancer immunotherapy Authors: Florian Van Oers, Zoi Katana, Donovan Flumens, Eva Lion, Diana Campillo-Davo Published: 2026 ABSTRACT AbstractElectroporation of messenger RNA (mRNA) is an ex vivo non-integrating gene transfer technique used in immune-cell-based trials for cancer to transiently supply immune cells with multiple proteins. This technique has been used to engineer dendritic cells and B cells with tumor-associated antigens to boost the immune system of cancer patients and to redirect the anti-tumor activity of T cells and natural killer cells with immune receptors. Although gene delivery via mRNA electroporation results only in transient expression of the protein of interest, many investigators and clinicians consider it as a feasible, flexible, and safe technique, compared with stable expression methods using viral vectors. In this review, we discuss the efficacy of mRNA electroporation for gene transfer and assess the strengths and limitations of this technique for redirecting and boosting immune responses against various tumor antigens in cancer immunotherapy.Keywords: MT: Delivery Strategies, RNA electroporation, messenger RNA, gene engineering, immunotherapy, cell therapy Introduction Gene therapy has revolutionized medicine in unprecedented ways. Among the multiple delivery systems used in gene transfer, electroporation of messenger RNA (mRNA) has been widely used in cancer immunotherapy to supply immune cells with a myriad of proteins. It offers a rapid, safe, and efficient method for genetically engineering immune cells. Electroporation is an efficient non-viral technology that uses an electric field to create pores in the cell membrane. Such transient disruption of cell membrane integrity allows the passage of extracellular genetic material and other molecules into the cytoplasm. In mRNA electroporation, protein-coding synthetic mRNA is added to the electroporation medium in order to induce the transient expression of proteins of interest. Different factors may affect mRNA transfection efficiency via electroporation and protein translation from transfected mRNA. These factors can be divided into three categories: (1) electroporation parameters, (2) in vitro transcription (synthesis) of mRNA, and (3) potential modifications of the mRNA sequence (reviewed in).1 As demonstrated by our group two decades ago, mRNA electroporation is superior to passive pulsing of peptides and proteins, lipofection of mRNA, and even electroporation of plasmid DNA.2,3 Over the years, the flexibility of mRNA electroporation, as well as its simplicity, ease of use, and safety compared to viral vectors, has been amply demonstrated in both preclinical and clinical settings.4,5 Thus, this tool may be used to engineer multiple immune cell types via various proteins for diverse purposes. This technique, which was first developed to load antigen-presenting cells (APCs) with mRNAs coding tumor antigens for the purpose of activating the host immune system against tumor cells, is being increasingly used to redirect and bolster the tumor-killing capacities of other immune cell types. This review summarizes the advances, benefits, and limitations of this form of gene transfer into different human primary cells for cancer immunotherapy and provides a foundation for designing mRNA-electroporation-based cell engineering workflows. mRNA electroporation of dendritic cells Dendritic cells (DCs), considered to be key orchestrators of the immune system, have attracted substantial attention as potential cellular vaccines for cancer, making the optimization of DC-based vaccines a strategic objective. Historically, this has been done using a range of technique.6,7,8 However, this section will focus on mRNA electroporation. Depending on the stage of DC development and the mRNA constructs used, this approach has been used in both human DCs and murine DCs to achieve several purposes9,10,11,12 (Table 1). For instance, electroporation of mRNAs has been used to induce DC maturation, load mature DCs with tumor-associated antigens (TAAs), increase DC immunogenicity, and finally, to introduce mRNAs encoding secondary molecules into DCs. In this section, we will elaborate more on these four purposes. Table 1Electroporation settings for dendritic cellsCell typeGene(s)/Antigen(s)EP system (company)Type of pulseVoltage (V)Capacitance (μF)Time (ms)Gap (mm)Buffer (μL)Amount of mRNA (μg)Cell number (×106cells)Cell concentration (×106 cells/mL)% protein expression (time point)ReferenceIL-4 DCsGFP, CHO-GITR, CHO-CTLA-4ECM830 (BTX)SW300ND0.52100–200n.a.n.a.25–30NDLee et al.12BM-derived mouse IL-4 DCseGFP, OVAEasyJect Plus (EquiBio)ND300150642002042077% eGFP (24 h)Van Meirvenne et al.9BM-derived mouse IL-4 DCseGFP, CEAGene Pulser (BTX)SW300n.a.0.52200201540% eGFP (24 h)Kim et al.10IL-4 DCsTriMix, MelanA-A2, NGFREasyJect Plus (EquiBio)ND300150n.a.NDND10–204n.a.∼60% CD40L (4 h), 78% CD70 (24 h)Bonehill et al.14BM-derived mouse IL-4 DCsTagBFPGene Pulser Xcell (Bio-Rad)ED300150n.a.42001042090.8% (24 h)Bialkowski et al.15IL-4 DCsTriMix, MAGE-A3, MAGE-C2, tyrosinase, gp100Gene Pulser Xcell (Bio-Rad)ND300450n.a.460020 μg TriMix +60 μg TAA encoding mRNA.5083.3NDBenteyn et al.16Immature IL-4 DCsTriMixGene Pulser Xcell (Bio-Rad)SWNDNDNDND200NDNDNDNDPen et al.18IL-4 DCsTriMix, Melan-A2, MAGE-A3, MAGE-C2, tyrosinase, gp100EasyJect Plus (EquiBio)ND300450n.a.ND60020 μg TriMix +60 μg TAA encoding mRNA.5083.3∼80% CD70 (24 h)Bonehill et al.19BM-derived mouse IL-4 DCsOVA, tyrosinase, WT1, tNGFR, TriMixEasyJect Plus (EquiBio)ND3001506420020420NDVan Lint et al.23IL-4 DCsPSA-1, MART-1, MART-1-APLND (Bio-Rad)NDNDNDND45002 μg/10ˆ6 cells TAA +4 μg/10ˆ6 cells CD40L2040Dependent on the protocolCalderhead et al.24Immature IL-4 DCsMAGE-A3 with different signal sequences (Ii, LAMP1, DC-LAMP)EasyJect Plus (EquiBio)ND300150∼5420020 or 404 or 820–407–17 × 10e3 (relative expression in qPCR)Bonehill et al.28IL-4 DCs16 different constructsGene Pulser Xcell (Bio-Rad)SW500n.a.14100–60050 μg/mLn.a.30–6065.62% MelanA (24 h)Hoyer et al.30IL-4 DCsdifferent WT1 constructsGene Pulser Xcell (Bio-Rad)ND300150ND420020840NDBenteyn et al.32IL-4 DCsWT1Gene Pulser Xcell (Bio-Rad)TC300n.a.74200–50020max 50n.a.NDSmits et al.33IL-4 DCsWT1, TriMix (CD40L, caTLR4, CD70)EasyJect Plus (EquiBio)ND300150n.a.NDND20 μg WT1 and 5 μg of each of the TriMix mRNAs4–5n.a.NDBenteyn et al.34IL-4 DCsgp100, tyrosinaseGene Pulser Xcell (Bio-Rad)ED300150n.a.4200201260.NDSchuurhuis et al.41IL-4 DCseGFP, MelanA1, NGFR, IMP-1EasyJect Plus (EquiBio)ND300150/4505–64200/6003012 or 5060 or 83.358% (X-15), 76% (Optimix)Tuyaerts et al.44IL-4 DCsMUC1Gene Pulser II (Bio-Rad)ND300 V/cm150n.a.420082–810–4020 (relative quantification with RT-qPCR)Chen et al.45IL-4 DCsMiHA mRNA (P2x5, HMHA1)Gene Pulser II (Bio-Rad)ED200150NDNDND20NDNDNDRoeven et al.46IL-4 DCsP2x5Gene Pulser II (Bio-Rad)ND300150ND–20020NDND10∧2 relative expression (RT-qPCR) (24 h)Overes et al.47IL-4 DCsMiHA mRNA (P2x5, HMHA1)Gene Pulser II (Bio-Rad)ND200–300150n.a.420020NDNDNDHobo et al.48IL-4 DCsGagEasyJect Plus (EquiBio)ND300150NDNDND204n.a.“all cells displayed strong intracellular Gag expression”De Keersmaecker et al.52IL-4 DCsMUC4, survivinGene Pulser II (Bio-Rad)NDNDNDND450020 μg per construct5–2010–40NDChen et al.49IL-4 DCswhole tumor RNANucleofector (Amaxa)Program U16NDNDNDND1002 μL (conc. 500 ng/mL - 20 μg/mL)0.5–105–100NDMilano et al.50Immature IL-4 DCswhole tumor RNAECM830 (BTX)SW500ND0.3ND1001.5 μg/10e6 cells11087.8% eGFP (24 h)Gholamin et al.51IL-4 DCsMelanANDSW500n.a.0.5–14100–60050 μg/mLmax 60n.a.89.3% (4 h)Schaft et al.58DCsp53, survivin, hTERT, eGFP, CEFECM830 (BTX)SW500ND244005922.5NDBorch et al.59Immature IL-4 DCsFoxP3ECM830 (BTX)SW300n.a.0.5220015–205–625–30NDDevi et al.60IL-4 DCsGPC3, HLA-A2Gene Pulser Xcell (Bio-Rad)ED300150n.a.NDND35 μg GPC360 μg HLA-A2NDNDHLA-A2: 4% (3 h)–56% (24 h)GPC3: 24% (3 h)Dargel et al.61IL-4 DCsHLA-A2ECM830 (BTX)SW1250 V/cmn.a.3NDNDNDNDNDNDAbrahamsen et al.62IL-4 DCseGFP, M1ECM830 (BTX)SW500ND14250251.255∼90% (24 h)Met et al.63IL-4 DCsgp100, tyrosinase, CEAGene Pulser Xcell (Bio-Rad)ED300150ND420020105081% gp100, 12% tyrosinase, 76% CEA (24 h)Schuurhuis et al.43SW400ND0.6IL-4 DCseGFP, MAGE-A3, MelanAEasyJect Plus (EquiBio)ND300150ND4NDNDNDND89.1% (24 h maturation post EP) or 93.4% (EP post maturation)Michiels et al.64IL-4 DCsOSP-IL-15, IL-15RaGene Pulser Xcell (Bio-Rad)TC300ND742005 μg per constructNDNDhighVan den Bergh et al.65IL-4 DCsIL-15, IL-15RaGene Pulser Xcell (Bio-Rad)TC300n.a.7420010 μg per constructNDNDNDVan den Bergh et al.67IL-4 DCsCD62E/CD62LGene Pulser Xcell (Bio-Rad)SW500n.a.14100–60050 μg/mLn.a.30–6096% (28 h)Dorrie et al.70IL-4 DCsIFN-α, WT1Gene Pulser Xcell (Bio-Rad)TC300n.a.7420010 μg per constructNDND>4 × 103 IU IFN-α/5 × 105 DCsWillemen et al.72IL-4 DCsIL-21, MART-1, eGFP, IL-12EasyJect Plus (EquiBio)ND300150n.a.420010NDND90% eGFP (24 h), 600 pg/million cells IL-21Turksma et al.73Immature IL-4 DCstNGFR, sPD-1, sPD-L1Gene Pulser Xcell (Bio-Rad)ND3001505–6–20020420secretion measured, but mentioned as OD valuePen et al.74IL-4 DCsanti-DcR3 mAbGene Pulser II (Bio-Rad)SW500n.a.0.345003-10 μg5–2010–40<15% but high secretion (24 h)Chen et al.75IL-15 DCseGFP, M1Gene Pulser Xcell (Bio-Rad)ED3001507420020 (eGFP)10 (M1)1550%–75% (4 h, 24 h, 48 h)Anguille et al.207IL-4 DCsHSP70NDND400ND0.5ND4001025NDMatsui et al.208IL-4 DCsTriMix, tyrosinase, gp100, MAGE-A3, MAGE-C2NDND300450NDND60020 μg TriMix, 60 μg other constructs5083.3NDDe Keersmaecker et al.20IL-4 DCsTriMix, tyrosinase, gp100, MAGE-A3, MAGE-C2NDND300450NDND60020 μg TriMix, 60 μg other constructs5083.3NDJansen et al.22IL-4 DCscaIKKβ, chIL15NDSW500ND1410030660NDBosch et al.68IL-4 DCsTMG-VALGene Pulser Xcell (Bio-Rad)ND300150ND42001 μg/106 cells4–1620–80NDIngels et al.209Langerhans DCs; derived from CD34+ HPCsCT7, MAGE-A3, WT1ECM830 (BTX)ND700NDND220040315NDChung et al.40IL-4 DCsgp100, tyrosinase, PRAME, MAGE-A3, IDO1, and/or IKKβ mRNANDSW500ND14NDNDNDNDNDKoch et al.42IL-4 DCsTrimix, TetramixGene Pulser Xcell (Bio-Rad)ND500ND2ND200100 μg/mLNDNDNDde Mey et al.21IL-4 DCsWT1Gene Pulser Xcell (Bio-Rad)ND300ND7420010 or 2020100NDBerneman et al.39IL-4 DCseGFPGene Pulser Xcell (Bio-Rad)ND300ND74ND12 per wellND>95%Lambart et al.210IL-15 DCsWT1-DC-LAMPGene Pulser Xcell (Bio-Rad)ED300150NDND2501 μg/106 cells52047.31%–53.27%Versteven et al.211APL, altered peptide ligand; BM, bone marrow; B7-H7, human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2); C, capacitance; calKKbeta, constitutively active inhibitor of nuclear factor κB kinase subunit beta; caTLR4, constitutively active Toll-like receptor 4; CD62E, CD62 antigen-like family member E (E-selectin); CD40L, CD40 ligand; CD62L, CD62 antigen-like family member L (L-selectin); CEA, carcinoembryonic antigen; CEF, cytomegalovirus, Epstein-Barr virus, and influenza virus; chIL15, chimeric IL-15/IL-15R; CHO-GITR, Chinese-hamster-ovary-cell-derived glucocorticoid-induced tumor necrosis factor receptor; CHO-CTL4, Chinese-hamster-ovary-cell-derived cytotoxic T-lymphocyte-associated protein 4; DC, dendritic cell; DC-LAMP, dendritic cell-lysosome-associated membrane protein; ED, exponential decay; eGFP, enhanced green fluorescent protein; EP, electroporation; FoxP3, forkhead box P3; Gag, group-specific antigen; GFP, green fluorescent protein; gp100, glycoprotein 100; h, hours; HSP70, heat shock protein 70; hTERT, human telomerase reverse transcriptase; IDO1, indoleamine 2,3-dioxygenase 1; IFN-α, interferon alpha; IL, interleukin; IMP-1, influenza matrix protein 1; LAMP, lysosome-associated membrane protein; M1, matrix protein 1; mAb, monoclonal antibody; MAGE, melanoma-associated antigen; MART-1, melanoma antigen recognized by T cells 1; MelanA, melanoma antigen recognized by T cells; MiHA, minor histocompatibility antigen; mRNA, messenger RNA; MUC1, mucin1; n.a., not applicable; n.d., no data; NGFR, nerve growth factor receptor; PRAME, preferentially expressed antigen in melanoma; OVA, ovalbumin; P2x5, purinoceptor 5; p53, tumor protein 53; PSA-1, prostate-specific antigen 1; Ref., reference; siRNA, small interfering RNA; sPD-1, soluble programmed death protein 1; sPD-L1, soluble programmed death receptor ligand 1; SW, square wave; TagBFP, blue fluorescent protein; TC, time constant; TMG-VAL, tandem of minigenes encoding three HLA-A2-restricted model epitopes, CMVpp65:495-503, gp100:280-288, and MART-1:26-35; tNGFR, truncated rat nerve growth factor receptor; TriMix, mRNA encoding CD70, CD40L, and a constitutively active Toll-like receptor 4; WT1, Wilms’ tumor 1. Electroporation settings for dendritic cells APL, altered peptide ligand; BM, bone marrow; B7-H7, human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2); C, capacitance; calKKbeta, constitutively active inhibitor of nuclear factor κB kinase subunit beta; caTLR4, constitutively active Toll-like receptor 4; CD62E, CD62 antigen-like family member E (E-selectin); CD40L, CD40 ligand; CD62L, CD62 antigen-like family member L (L-selectin); CEA, carcinoembryonic antigen; CEF, cytomegalovirus, Epstein-Barr virus, and influenza virus; chIL15, chimeric IL-15/IL-15R; CHO-GITR, Chinese-hamster-ovary-cell-derived glucocorticoid-induced tumor necrosis factor receptor; CHO-CTL4, Chinese-hamster-ovary-cell-derived cytotoxic T-lymphocyte-associated protein 4; DC, dendritic cell; DC-LAMP, dendritic cell-lysosome-associated membrane protein; ED, exponential decay; eGFP, enhanced green fluorescent protein; EP, electroporation; FoxP3, forkhead box P3; Gag, group-specific antigen; GFP, green fluorescent protein; gp100, glycoprotein 100; h, hours; HSP70, heat shock protein 70; hTERT, human telomerase reverse transcriptase; IDO1, indoleamine 2,3-dioxygenase 1; IFN-α, interferon alpha; IL, interleukin; IMP-1, influenza matrix protein 1; LAMP, lysosome-associated membrane protein; M1, matrix protein 1; mAb, monoclonal antibody; MAGE, melanoma-associated antigen; MART-1, melanoma antigen recognized by T cells 1; MelanA, melanoma antigen recognized by T cells; MiHA, minor histocompatibility antigen; mRNA, messenger RNA; MUC1, mucin1; n.a., not applicable; n.d., no data; NGFR, nerve growth factor receptor; PRAME, preferentially expressed antigen in melanoma; OVA, ovalbumin; P2x5, purinoceptor 5; p53, tumor protein 53; PSA-1, prostate-specific antigen 1; Ref., reference; siRNA, small interfering RNA; sPD-1, soluble programmed death protein 1; sPD-L1, soluble programmed death receptor ligand 1; SW, square wave; TagBFP, blue fluorescent protein; TC, time constant; TMG-VAL, tandem of minigenes encoding three HLA-A2-restricted model epitopes, CMVpp65:495-503, gp100:280-288, and MART-1:26-35; tNGFR, truncated rat nerve growth factor receptor; TriMix, mRNA encoding CD70, CD40L, and a constitutively active Toll-like receptor 4; WT1, Wilms’ tumor 1. Classically, immature DCs are treated with a mixture of cytokines in order to induce maturation.13 However, electroporation with specific mRNAs can also be used for this purpose. A combination of three different mRNAs coding for a cluster of differentiation (CD)70, CD40 ligand (CD40L), as well as constitutively active toll-like receptor 4 (caTLR4) have been co-electroporated into immature DCs to induce maturation.14,15 This combination is named TriMix, and the resulting TriMix-electroporated DCs have been used in several studies.16,17,18,19,20,21,22 A major advantage of these DCs is that they do not require a 48-h maturation period, which can potentially result in DC exhaustion. Because mature molecules are rapidly expressed, TriMix-electroporated DCs can be delivered to a patient within a few hours following electroporation.16 Furthermore, other studies have indicated that this protocol is compatible with simultaneous electroporation of tumor antigen mRNA.16,17,20,22,23 The newly developed TetraMix replaces CD70 in TriMix with interferon (IFN)-γ and a decoy interleukin (IL)-10 receptor α, shifting from an antibacterial to an antiviral maturation profile capable of inducing stronger tumor-specific CD8+ T cell responses than TriMix-electroporated DCs.21 In addition, others have combined a short maturation process, using pro-inflammatory cytokines IFN-γ and tumor necrosis factor alpha, with co-electroporation with TAA-encoding mRNA and CD40L mRNA.24,25 IL-12 secretion by DCs treated in this manner was improved compared to that by DCs not electroporated with CD40L mRNA. Moreover, DCs treated with both a pro-inflammatory cytokine cocktail and CD40L mRNA demonstrated superior induction of CD8 T cell cytolytic activity.24 Considered together, these studies demonstrated the importance of mRNA-electroporation-mediated DC maturation. Consequently, several clinical trials using this maturation approach as a DC vaccine for melanoma have either been conducted or are currently being conducted (clinicaltrials.gov identifiers: NCT01302496, NCT01066390, NCT01530698, NCT01676779, NCT00074230, and NCT02170389). Antigen delivery is probably the most common application of mRNA electroporation in DCs. It is routinely accomplished by either pulsing DCs with one or more peptides or by electroporating tumor-antigen-specific mRNA. The latter technique offers important advantages over the use of peptide pulsing. For example, electroporation of the full-length sequence of TAA results in a multi-epitope DC vaccine, which also presents TAA epitopes that may be currently unknown.26 Furthermore, this approach allows DC vaccines to be generated without prior knowledge of a patient’s human leukocyte antigen (HLA) haplotype.27 As DCs electroporated with TAA-encoding mRNA are capable of presenting TAA epitopes by both HLA class I and class II molecules, these are able to stimulate both CD8 and CD4 T cells.28,29 While both these advantages also apply to the transduction of DCs with a TAA-encoding plasmid, mRNA electroporation results in transient expression, which does not pose a risk of being integrated into the host genome, indicating that it is a clinically safer vaccine. Furthermore, mRNA electroporation displays a higher transfection efficiency compared to that of plasmid DNA transduction.2,30 One study tested 16 different constructs comprised of several TAAs and found electroporation to be a highly efficient method for introducing TAA-mRNA without affecting the phenotype of the DCs.30 These observations demonstrate the broad applicability of this technique and account for the wide variability seen in TAAs selected for mRNA electroporation of DCs. Frequently used TAAs (previously reviewed)31 include Wilms’ tumor protein 1 (WT1),17,32,33,34,35,36,37,38,39,40 melanoma-associated antigens MAGE-A3 and MAGE-C2,28 glycoprotein 100 (gp100),41 tyrosinase,19,20,22,23,41,42,43 melanoma antigen recognized by T cells 1 (MART-1),24,25,44 and mucin 1 (MUC1).45 Several minor histocompatibility antigens, including mRNAs encoding for purinergic receptor P2X5 and minor histocompatibility protein HA-1, have also been electroporated into DCs.46,47,48 DCs can be electroporated with multiple mRNAs to prevent immune escape by tumor cells via downregulation of TAAs. For instance, in a pancreatic cancer model, DCs co-electroporated with MUC4 mRNA and survivin mRNA induced stronger cytotoxic T cell responses, compared to that of DCs electroporated with a single mRNA.49 To further maximize the number of T cells reacting to an antigen-specific DC vaccine and to ensure all tumor-derived antigens are presented by DCs, several groups have electroporated whole tumor mRNAs into DCs.50,51 In addition, mRNA encoding viral antigens, including human immunodeficiency virus proteins,52,53,54 human cytomegalovirus pp65 antigen,55 and mRNA encoding antigens related to autoimmune disorders,56 have been electroporated into DCs. TAA-mRNA-loaded DCs are currently being used in a large number of clinical trials.57 However, in addition to being used in clinical studies, the antigen-specific immune stimulating properties of these DCs can be used to investigate key aspects of DC electroporation, which helps enhance preclinical development of this process.58 In this regard, mRNA-electroporated DCs have been used to investigate their long-term immunological impact via immunomonitoring.59 Furthermore, TAA-mRNA-electroporated DCs have been used to stimulate and expand CD8 T cells ex vivo in order to generate antigen-specific T cell clones60 from which immunodominant T cell receptors (TCRs) can be isolated for the purpose of adoptive T cell transfer.61,62 A consensus on the culture stage that is optimal for electroporation of TAA-mRNA has not yet been reached. While the main function of immature DCs is antigen uptake, mature DCs are more suited for antigen presentation. Studies investigating the optimal time point for mRNA electroporation of DCs have indicated that electroporation using mature DCs results in a higher viability compared to that using immature DCs.63 This study also showed that electroporation of DCs following maturation results in greater capability to induce antigen-specific T cell responses.63 Interestingly, the capacity for transgene expression is dependent on the maturation cocktail used. For example, Schuurhuis et al. demonstrated that DC maturation in the presence of polyinosinic:polycytidylic acid [poly(I:C)] results in decreased protein expression following mRNA electroporation.43 Another study showed that DCs electroporated after maturation have a better migratory capacity compared to immature DCs subjected to mRNA electroporation.64 Despite findings favoring electroporation of DCs post-maturation, TAA-mRNA electroporation is still performed using both immature and mature DCs. Double electroporation of both immature and mature DCs was tested, resulting in a substantial decrease in DC viability and yield.46 DCs have been electroporated using several constructs to increase their immunogenicity. Co-electroporation of DCs with mRNA coding for IL-15 and the α-chain of the IL-15 receptor resulted in the trans-presentation of IL-15 on the membrane of IL-4 DCs. This proved to be a successful strategy for increasing tumor-antigen-specific T cell activation.65,66 Furthermore, these IL-15 trans-presenting DCs are able to activate natural killer (NK) cells, in contrast to conventional IL-4 DCs.67 Similar effects were observed in DCs electroporated with constitutively active IκB kinase beta (caIKKβ), which activates the nuclear factor κB (NF-κB) pathway and promotes IL-12-driven stimulation of NK cells and cytotoxic T cells.42,68 Electroporation of DCs with CD40L or OX40 ligand (OX40L) mRNA also increases immunogenicity, as these deliver important costimulatory signals to T cells during DC/T cell interaction.18,25,69 Another strategy used to increase the immunogenicity of DCs is to increase their migration to regional lymph nodes. This is accomplished by electroporating DCs to express a human chimeric CD62/CD62 ligand (CD62L) protein.70 A final application of using DCs for mRNA electroporation is the delivery of other molecule types. As DCs possess the capacity to move toward lymph nodes and interact with a multitude of effector cells,71 they are exceptionally well suited for the production of immune modulatory molecules at these locations. As such, IFN-α mRNA-electroporated DCs have been recognized as potent inducers of adaptive and innate anti-tumor immunity.72 Similarly, IL-21 mRNA-electroporated DCs have increased the cytotoxicity of TAA-specific T cells.73 With immune checkpoint blockade being increasingly used in combination with DC vaccination, in situ delivery of checkpoint inhibitors presents an interesting approach. The soluble portion of programmed death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1), encoded via mRNA molecules, is produced at T cell interaction sites, leading to an increase in the number of multifunctional T cells and downstream cytokine secretion.74 Similarly, DCs have been electroporated with mRNA encoding the heavy and light chain of an antibody specific for DcR3, a decoy receptor for the Fas ligand that is overexpressed in a number of tumors and known to promote tumor growth.75 These DCs, which are co-electroporated with TAA-encoding mRNA, secrete anti-DcR3 antibodies, leading to increased tumor-specific T cell activation.75 Electroporation of DCs with antibody-encoding mRNAs has also been described for antibodies targeting the glucocorticoid-induced tumor necrosis factor receptor (TNFR) (GITR) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).76,77 Moreover, this strategy has also been evaluated in a clinical trial for patients with metastatic melanoma; however, no results were ever published (clinicaltrials.gov identifier: NCT01216436). mRNA electroporation of T cells T cell receptor gene transfer T cells have been widely used in cancer immunotherapy due to their anti-tumor effector activity.78 They possess highly specialized TCRs that are able to recognize internally processed peptides presented by the major histocompatibility complex (MHC), including TAAs. Due to negative selection of auto-reactive T cells, there is a scarcity of T cells that are able to recognize TAAs, especially those that are autoantigens. In order to circumvent this difficulty, T cells are engineered with TAA-specific TCR mRNAs isolated from TAA-reactive T cells.79,80 Considering the transient nature of mRNA electroporation, strategies that achieve optimal TCR expression assume importance. TCR expression can be enhanced by increasing correct TCR pairing, reducing CD3 competition with endogenous TCRs, or by improving TCR affinity. For example, chains from endogenous and transgenic TCRs may pair incorrectly when a secondary TCR is expressed in a T cell. This can be prevented via humanized or murinized TCR chains (for murine- or human-derived TCRs, respectively),81,82,83 additional interchain disulfide bonds,84 single-chain TCRs,85 swapping human TCR chain domains,86 or a combination of these techniques.85,87 Our group has shown that electroporation of silencing RNAs (siRNAs) or the clustered regularly interspaced short palindromic repeats-CRISPR-associated protein (CRISPR/Cas) system targeting the T cell receptor alpha constant and T cell receptor beta constant domains downregulates the expression of endogenous TCR chains. This, in turn, improves both CD3 availability and the pairing of transgenic TCR.88,89 High-affinity anti-tumor TCRs, showing improved interaction between TCR and the peptide-MHC (pMHC) complex, rarely occur naturally. However, they can be generated by using humanized mice,90 mismatched HLA donors,91 or phage display techniques92 and may be further optimized via genetic mutation.93,94 Various tumor antigens, including MART-1,79,82,83,84,94,95,96 tumor protein p53,79,82,83,84,85 WT1,88 carcinoembryonic antigen (CEA),97 gp100,82,85,87,98,99 chaperonin-containing TCP1 subunit 6A,99 and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), have been targeted with TCR-mRNA-electroporated T cells (Table 2).79,83,84,92,94 However, other types of antigens also expressed in cancer cells such as viral antigens100,101,102 and neoantigens99,103 can be targeted using TCR-mRNA-redirected T cells. Inderberg and colleagues isolated a TCR directed against a frameshift mutation in transforming growth factor β receptor II (TGFβRII), which is present in the majority of microsatellite unstable colon cancers.103 In a xenograft transplantation model, anti-TGFβRII TCR-mRNA-modified T cells reduced tumor burden and prolonged survival following repeated intraperitoneal injections, in contrast to that observed following repeated intravenous (IV) injections.104 Lack of activity following IV injections suggests that transiently modified T cells may benefit from injection near the tumor site, as trafficking long distances prior to encountering tumor cells may reduce TCR availability. In 2018, the use of these anti-TGFβRII TCR-mRNA-modified T cells received approval for a first-in-human trial involving TCR-mRNA transfection (clinicaltrials.gov identifier: NCT03431311; Table 3). Only one patient was recruited eventually, who maintained stable disease for 6 months after treatment and showed a favorable safety profile without significant toxicities.105 Table 2Electroporation settings for T cells with T cell receptorsCell typeTCR specificityRestrictionCancer typeEP system (company)Type of pulseVoltage (V)Time (ms)EP gap (mm)EP buffer (μL)Amount of mRNA (μg)Cell number (×106 cells)Cell concentration (×106 cells/mL)% TCR expression (time point)ReferenceStimulated CD8 T cells from melanoma patientsNY-ESO-1, MART-1 and p53 TCRHLA-A2melanomaECM830 (BTX)SW4000.5250–2002 μg/106 cells1.25–52545%–65% (ON)Zhao et al.79CD8 T cellsgp100HLA-A2melanomaGene Pulser Xcell (Bio-Rad)SW50054100–600150 μg/mL8–488093% eGFP (4 h) low % TCR (24 h)Schaft et al.80Expanded PBLsMART-1, gp100, p53HLA-A2melanomaECM830 (BTX)SW4000.52ND1 μg/106 cellsn.a.2069%–72% (24 h)Bialer et al.82Expanded PBLs from melanoma patientsMART-1, p53, NY-ESO-1HLA-A2 (MART-1, p53)HLA-DP4 (NY-ESO-1)melanomaECM830 (BTX)SW5000.52ND2 μg/106 cellsn.a.2521%–93% (24 h)Cohen et al.83Expanded PBLs from melanoma patientsMART-1, NY-ESO-1, p53HLA-A2melanomaECM830 (BTX)SW5000.52ND1.5 μg/106 cellsn.a.2529%–85% (24 h)Cohen et al.84CD8 T cellsgp100, p53HLA-A2melanomaGene Pulser Xcell (Bio-Rad)SW49510NDND≤20NDND35%–77% (20 h)Knies et al.85J76 Jurkat cellsgp100HLA-A2melanomaGene Pulser Xcell (Bio-Rad)SW5004ND2001042018.5%–99% (next day)Voss et al.87Resting CD8 T cellsWT1HLA-A2leukemiaGene Pulser Xcell (Bio-Rad)SW500542001 μg/106 cells10–2050–10019%–42% (24 h)Campillo-Davo et al.88Stimulated CD4/CD8 T cells from metastatic melanoma patientsNY-ESO-1HLA-A2melanomaECM830 (BTX)SW4000.5250–2002 μg/106 cells1.25–52516%–88% (ND)Zhao et al.92Stimulated CD4/CD8 T cellsNY-ESO-1, MART-1HLA-A2melanomaECM830 (BTX)SW4000.5250–2002 μg/106 cells1.25–525NDRobbins et al.94CD8 T cellsMART-1HLA-A2melanomaGene Pulser Xcell (Bio-Rad)SW50054100–600150 μg/mL8–4880NDBirkholz et al.95Expanded T cellsMART-1HLA-A2melanomaNDNDNDNDND400.5–21251%–25% (2–16 h)Johnson et al.96Stimulated CD4/CD8 T cellsCEAHLA-A2colorectal cancerECM830 (BTX)SW5000.5250–2002 μg/106 cells1–42072%–78% (24 h)Parkhurst et al.97Expanded γδ T cells and CD8 T cellsgp100HLA-A2melanomaGene Pulser Xcell (Bio-Rad)SW50054ND15n.a.110%–28.9% (24 h)Harrer et al.98CD8 T cellsgp100, patient-specific neoantigenHLA-A2, HLA-B27melanomaGene Pulser Xcell (Bio-Rad)SW5005NDNDVariableNDNDNDHofflin et al.99Expanded CD8 T cellsHBV envelopeHLA-A2HBV-related HCCNucleofector 2b (Lonza)X-001NDNDND10010–205–2050–20080% (24 h)Koh et al.100Expanded CD4/CD8 T cellsTGFβRII frameshift mutationHLA-A2colorectal cancerECM830 (BTX)SW50024ND100 μg/mLn.a.7060%–70% (ON)Inderberg et al.103Expanded CD4/CD8 T cellsTGFβRII frameshift mutationHLA-A2Colorectal cancerECM830 (BTX)SW50024ND100 μg/mLn.a.7075%–85% (18 h)Mensali et al.104Fresh and thawed expanded T cellshTERTHLA-DP4Generally expressed in all cancer formsECM830 (BTX)SW50024800100 μg/mL4590% (17 h)Kyte et al.106Expanded T cellsallo-HLA-DPB1∗04:01,allo-HLA-DPB1∗03:01––Gene Pulser Xcell (Bio-Rad)SW50054ND10 μg per TCR chain5–10ND96% (16–20 h)Klobuch et al.107PBMCs. Expanded T cells and γδ T cellsα-GalCer (semi-invariant NKT receptor)CD1dNDECM830 (BTX)SW5003NDND10NDND60%–70% (12 h); 54% (24 h)Shimizu et al.109PBMCsNY-ESO-1, TyrosinaseHLA-A2, HLA-B7, HLA-DRB0401TCR-engineered reference samplesECM830 (BTX)SW5003425030208040%–60% (18–-20 h)Bidmon et al.110PBMCsNY-ESO-1, Influenza, TyrosinaseClass ITCR-engineered reference samplesECM830 (BTX), Multiporator (Eppendorf), Gene Pulser II (Bio-Rad), Gene Pulser Xcell (Bio-Rad), Nucleofector II (Lonza), Amaxa 4D (Lonza)SW/ED200–1,0000.05–15 ms (SW)150–1,500 μF (ED)4 (Bio-Rad); Nucleocuvette Vessel/Strip (Lonza)20–2502–10 (Flu-TCR), 10–75 (TAA-TCRs and Flu-TCR in ECM830)1–5 (Flu-TCR), 10–60 (TAA-TCR and Flu-TCR in ECM830)n.a.61%–90% (ON)Bidmon et al.112Expanded CD8 T cellsWT1HLA-A2leukemiaNucleofector Xcell (Bio-Rad)ED300ND8200–40016, 32, 1 μg/106 cells10–205066.9% WT1.37, 72.4% WT1.126Campillo-Davo et al.212Expanded T cellsHBVHLA-A2HBV-related HCC4D-Nucleofector (Lonza)NDNDNDNDND20 μg/106 cells5–10NDNDCeccarello et al.213Expanded T cellshTERTHLA-DP04, HLA-DP03generally expressed in all cancer formsECM830 (BTX)SW50024ND100 μg/mLND7096.1%Dillard et al.214Expanded T cellsTGFβRII frameshift mutationHLA-A2colorectal cancerAgilePulse MAX (BTX)ND7700.46ND200 μg/mLNDNDNDMaggadottir et al.105allo-, allogeneic; CEA, carcinoembryonic antigen; CnB, mutated variants of calcineurin B; ED, exponential decay; EP, electroporation; gp100, glycoprotein 100; h, hours; HBV, hepatitis B virus; HBsAG, hepatitis B virus surface antigen; HbcAG, hepatitis B virus core antigen; HCC, hepatocellular carcinoma; HLA-, human leukocyte antigen-type; hTERT, human telomerase reverse transcriptase; IMPDH, inosine-5′-monophosphate dehydrogenase; MART-1, melanoma antigen recognized by T cells 1; mRNA, messenger RNA; n.a., not applicable; n.d., no data; NKT, natural killer T cell; NY-ESO-1, New York esophageal squamous cell carcinoma 1; ON, overnight; PBMC, peripheral blood mononuclear cell; PBL, peripheral blood lymphocyte; Ref., reference; SW, square wave; TCR, T cell receptor; TGFβRII, transforming growth factor beta receptor II; WT1, Wilms’ tumor 1; α-GalCer, α-galactosylceramide. Electroporation settings for T cells with T cell receptors allo-, allogeneic; CEA, carcinoembryonic antigen; CnB, mutated variants of calcineurin B; ED, exponential decay; EP, electroporation; gp100, glycoprotein 100; h, hours; HBV, hepatitis B virus; HBsAG, hepatitis B virus surface antigen; HbcAG, hepatitis B virus core antigen; HCC, hepatocellular carcinoma; HLA-, human leukocyte antigen-type; hTERT, human telomerase reverse transcriptase; IMPDH, inosine-5′-monophosphate dehydrogenase; MART-1, melanoma antigen recognized by T cells 1; mRNA, messenger RNA; n.a., not applicable; n.d., no data; NKT, natural killer T cell; NY-ESO-1, New York esophageal squamous cell carcinoma 1; ON, overnight; PBMC, peripheral blood mononuclear cell; PBL, peripheral blood lymphocyte; Ref., reference; SW, square wave; TCR, T cell receptor; TGFβRII, transforming growth factor beta receptor II; WT1, Wilms’ tumor 1; α-GalCer, α-galactosylceramide. Table 3Clinical application of mRNA-electroporated T cells and natural killer cells for cancer therapyClinical trial identifierType of malignancyStudy phaseRecruitment statusCell typeGene(s)No. subjects treated/enrolledTrial treatmentResponseFeasibilitySafetyReferenceNCT01355965MPleMIcompletedautologous T cellsanti-Meso scFv-BBz CAR4/18repeated infusionsPR in one patientCAR-T cell manufacturing was possible for 4 patients. 21 infusions were administered in total.well tolerated, except for a case of treatment-related anaphylaxis and cardiac arrest from which the patient recovered. Possibly treatment-related Gr. III–IV AEs.Maus et al.141, Beatty et al.149NCT01837602metastatic (triple-negative) BC0/Icompletedautologous T cellsanti-cMet scFv-BBz CAR6/6single infusionno results availableCAR-T cells were successfully manufactured for all patients.well tolerated. No treatment-related Gr. >I AEs.Tchou et al.151NCT01897415PDACIcompletedautologous T cellsanti-Meso scFv-BBz CAR6/10repeated infusionsSD in two patientsCAR-T cell manufacturing was possible for 10 patients. Manufacture failure in one case.53 of 54 planned CAR-T cell infusions were administered.treatment-related Gr. III–IV AEs. No treatment-related deaths, CRS, neurologic symptoms, pleuro-pericarditis, or peritonitis. No DLT.Beatty et al.150, Beatty et al.215NCT02277522/NCT02624258adult and pediatric HLIterminatedautologous T cellsanti-CD19 scFv-BBz CAR4/5repeated infusionsCR in one patient, SD in one patient, and PR in one patientCAR-T cells were successfully manufactured for all patients.well tolerated. No Gr. III–IV AEs. No CRS.Svoboda et al.152, Svoboda et al.216NCT02315118B-Cell CLLB-Cell NHLI//IIunknownautologous T cellsanti-CD16-BBz CAR6/6repeated infusionsSD in two patientsCAR-T cells were successfully manufactured for all patients.14 infusions were administered in total. Estimated minimum target levels of CAR-T cells were met in 13 of 14 products.no off-target effects, no CRS, no treatment-related AEs.Poon et al.217NCT02623582R/R AMLIterminatedautologous T cellsanti-CD123 scFv-BBz CAR5/7repeated infusionsPD in all patientsCAR-T cell manufacturing was attempted in 6 of the 7 enrolled patients. CAR-T cell manufacturing was possible in 5 patients. 14 of 24 planned CAR-T cell infusions were manufactured; all planned doses were successfully manufactured in 2/6 patients.no treatment-related deaths, clinically apparent vascular, neurological, or hematological toxicities. All infusions were followed by a fever with CRS (Gr. I–IV). All CRS episodes resolved within 1 day.Cummins et al.218NCT03060356R/R melanomametastatic triple-negative BCIterminatedautologous T cellsanti-cMet scFv-BBz CAR7/77repeated infusionsSD in four patients77 subjects were pre-screened for tumor cMet expression. 37 subjects met the eligibility threshold. CAR-T cell infusions were administered to 7 patients.well tolerated. Possibly or definitely treatment-related Gr. I–II AEs in 5 patients. No Gr. ≥III toxicities or CRS.Shah et al.219NCT03448978multiple myelomaI/IIterminatedautologous T cellsanti-BCMA scFv-28z CARno results availablerepeated infusionsno results availableno results availableno results available–NCT03608618ovarian cancerMPerMIterminatedautologous PBMCanti-Meso scFv-BBz CAR11/Recruitingrepeated infusionsSD in 4 patientsCAR-T cells were successfully manufactured for all patients.well tolerated. Gr. I–II AEs. One case of Gr. II pericarditis, fever and transient neutropenia clinically assessed as related severe AEs (resolved without further complications) due to on-target off-tumor effects and possibly Gr. I CRS. No neurotoxicity. No DLT.Annunziata et al.220NCT03431311CRCI//IIterminatedT cellsHLA-A2-restricted TGFβII-specific TCR1/1repeated infusionsSD in one patientTCR-T cells were successfully manufactured.well tolerated. No significant toxicities. Only low grade fever after infusion.Maggadottir et al.105NCT03415100metastatic CRCIunknownautologous/allogeneic NK cellsNKG2D-ED-DAP12 or -z CAR3/3repeated infusionsCR in one patient, SD in 2 patientsCAR-NK cells were successfully manufactured for all patients.no dose-limiting toxicities. No Gr. ≥III AEs.Xiao et al.182NCT05302037advanced cancers (ANGELICA)Irecruitingallogenic γδ T cellsNKG2DL CARs–repeated infusionsno results availableno results availableno results available–NCT04981691advanced refractory solid tumors (Amaretto)Iunknownautologous T cellsanti-MESO CAR-T–3 + 3 dose escalation designno results availableno results availableno results available–NCT02719782HBV-associated HCCIunknownautologous T cellsHBV-TCR6/6repeated infusionsPD in all patientsTCR-T cells were successfully manufactured for all 6 patients. In total, 43 infusions were administered.no CRS, neurotoxicity-like AEs, or treatment-related serious AE.Yang et al.221AEs, adverse events; AML, acute myeloid leukemia; BB, 4-1BB; BC, breast cancer; BCMA, B cell maturation antigen; CAR, chimeric antigen receptor; CD, cluster of differentiation; CLL, chronic lymphocytic leukemia; cMet, tyrosine-protein kinase Met; CR, complete response; CRC, colorectal cancer; DLT, dose-limiting toxicities; ED, extracellular domain; Gr., grade; HL, Hodgkin lymphoma; HLA, human leukocyte antigen; IL, interleukin; Meso, mesothelin; MPleM, malignant pleural mesothelioma; MPerM, malignant peritoneal mesothelioma; NK, natural killer cell; NKG2D, natural killer group 2 member D; NHL, non-Hodgkin lymphoma; PBMC, peripheral blood mononuclear cells; PD, progressive disease; PDAC, metastatic pancreatic ductal adenocarcinoma; PR, partial response; R/R, relapsed or refractory; scFv, single-chain fragment variable; SD, stable disease; TCR, T cell receptor; TGFβRII, transforming growth factor beta receptor II; -28z, CD28-CD3ζ signaling domain; -BBz, 4-1BB-CD3ζ signaling domain; -DAP12, DNAX activation protein of 12 kDa signaling domain; -z, CD3ζ signaling domain. Clinical application of mRNA-electroporated T cells and natural killer cells for cancer therapy AEs, adverse events; AML, acute myeloid leukemia; BB, 4-1BB; BC, breast cancer; BCMA, B cell maturation antigen; CAR, chimeric antigen receptor; CD, cluster of differentiation; CLL, chronic lymphocytic leukemia; cMet, tyrosine-protein kinase Met; CR, complete response; CRC, colorectal cancer; DLT, dose-limiting toxicities; ED, extracellular domain; Gr., grade; HL, Hodgkin lymphoma; HLA, human leukocyte antigen; IL, interleukin; Meso, mesothelin; MPleM, malignant pleural mesothelioma; MPerM, malignant peritoneal mesothelioma; NK, natural killer cell; NKG2D, natural killer group 2 member D; NHL, non-Hodgkin lymphoma; PBMC, peripheral blood mononuclear cells; PD, progressive disease; PDAC, metastatic pancreatic ductal adenocarcinoma; PR, partial response; R/R, relapsed or refractory; scFv, single-chain fragment variable; SD, stable disease; TCR, T cell receptor; TGFβRII, transforming growth factor beta receptor II; -28z, CD28-CD3ζ signaling domain; -BBz, 4-1BB-CD3ζ signaling domain; -DAP12, DNAX activation protein of 12 kDa signaling domain; -z, CD3ζ signaling domain. Although conventional αβTCR CD8 T cells are widely used in TCR engineering experiments, transfecting non-conventional immune cells or other types of immune receptors in addition to TCRs is increasingly attracting attention. Kyte et al. showed that HLA-class-II-restricted TCRs against telomerase-positive target cells, obtained from helper T cells isolated from long-term cancer survivors, can be used to transiently modify both CD4 and CD8 T cells.106 More importantly, due to the potential off-target specificities of allo-reactive TCRs, suicide genes such as RQR8 can be included in the mRNA sequence, in order to abrogate toxicities arising from these T cells.106 More recently, Klobuch et al. demonstrated the potential of using TCRs for helper T cells against allogeneic HLA class II DPB1 antigens, a rising candidate for graft-versus-leukemia reactions.107 The mRNAs of these TCRs can also be transfected into both CD4 and CD8 T cells, enabling these to effectively recognize human primary acute myeloid leukemia blasts. However, the reactivity of allogeneic TCRs must be carefully assessed, as they may potentially lead to off-target reactivities.91 Similar to CD4 T cells, other T cell types may possess advantageous properties that are yet to be fully exploited. For instance, the use of γδ T cells is an interesting approach. Although γδ T cells only represent a small fraction of peripheral blood T cells, they can be expanded ex vivo to clinically relevant numbers, both from healthy donors and patients.98,108 These T cells are characterized by γδTCRs, which do not mispair with αβTCRs. In a comparative analysis using a current good manufacturing practice (GMP)-adaptable protocol, Harrer et al. showed that γδ T cells are equally capable of expressing αβTCRs as conventional CD8 T cells and are just as efficient in their anti-tumor capacity.98 In fact, γδ T cells exhibited an even safer profile for adoptive therapy than CD8 T cells, due to less background secretion of cytokines, indicating that γδ T cells are an excellent alternative for anti-tumor TCR engineering.98 Another attractive approach in TCR engineering is the generation of T cells that express two additional receptors (TETARs).99 TETARs provide dual TAA specificity, which further addresses the issue of tumor immunoediting and escape. Höfflin et al. successfully transfected two TCRs, one against a common tumor antigen and the other against a patient-specific neoantigen.99 The investigators showed that titration of the mRNAs and murinization of the TCR chains, in order to avoid TCR mispairing between the introduced TCR chains and competition for cellular factors, were vital for the success of this technique. The transfer of innate receptors, such as semi-invariant natural killer T cell (NKT) receptors, to conventional and non-conventional T cells, which confers HLA-unrestricted anti-tumor NKT features109 to these, represents an interesting alternative to conventional TCR engineering. Transfection with NKT receptors enables the implementation of more potent allogeneic, universal T cell therapy platforms in cancer T cell immunotherapy, with particular reference to expanded γδ T cells.109 The flexibility and simplicity of TCR-mRNA electroporation facilitates the development of off-the-shelf TCR-engineered reference samples (TERS) to control antigen-specific T cell performance in functional assays, compared to other techniques that entail much more work.110,111 These TERS can be produced in a standardized fashion using multiple electroporation systems across different laboratories, thereby ensuring that aliquots of TERS would effectively control the performance, sensitivity, and deviations of common T cell assays.112 Chimeric antigen receptor gene transfer Chimeric antigen receptors (CARs) are another type of artificial immune receptors that have been widely applied over the past years. Contrary to TCRs, CARs bind to antigens expressed on the surface of cancer cells. This pattern of recognition is generally independent of MHC expression and circumvents the constraints posed by the MHC on TCRs. Therefore, modifying T cells with CARs allows virtually any surface antigen, including protein, as well as glycosylated and lipid epitopes, to be targeted. CARs usually consist of several protein regions fused together into one open reading frame. These regions include (1) an antigen recognition domain, frequently generated by coupling the variable light and heavy chains of an antibody through a flexible linker forming a single-chain variable fragment (scFv); (2) a hinge/transmembrane domain providing flexibility that allows proper binding of the scFv to the target antigen and anchors the protein to the cell membrane; and (3) a signaling region consisting of one or more costimulatory domains (e.g., CD28 and 4-1BB) as well as the CD3ζ signaling domain of the TCR complex. Five generations of CARs have been developed over the past two decades. The first three generations incorporated none, one, or at least two costimulatory domains, respectively, which help improve the efficacy and persistence of therapy. The fourth and fifth generation CARs are characterized by the co-expression of cytokines or membrane receptors following CAR activation. Although viral integration of CAR sequences into the host T cell genome has been the preferred method for producing CAR-T cells, concerns over potential adverse effects of permanently modified CAR-T cells, such as cytokine release syndrome (CRS) and neurotoxicity, have fostered the exploration of safer alternatives for CAR delivery. Due to the self-limiting nature of CAR-mRNA electroporated T cells, these cells may potentially alleviate the above concerns and serve as a platform that enables safe and effective screening of novel CARs. Currently, CAR-mRNA T cells are being used to target a range of antigens and malignancies, with the most extensively studied targets including CD19,113,114,115,116,117,118,119,120,121,122,123,124,125 mesothelin (Meso),120,126,127 melanoma-associated chondroitin sulfate proteoglycan (MCSP),98,128,129,130,131,132 human epidermal growth factor receptor 2 (HER2),133,134,135 and natural killer group 2 member D (NKG2D)136,137,138 (Table 4). CAR surface expression in CAR-mRNA-transfected T cells usually peaks between 4 and 24 h post-electroporation and lasts for at least 1 week. Variations in the expression pattern are attributed to the half-life of the mRNA, dilution of the CAR as a result of T cell proliferation, protein stability on the cell membrane, and characteristics of the domains incorporated into the CAR.113,128,139 Moreover, titration, purification and/or additional modification of CAR-mRNA may modulate CAR surface expression and consequently the antigen-specific effector functionality, while also minimizing induced cell death.114,115 Panjwani et al. reported findings from a preclinical trial in large animals, in which pet dogs with spontaneous lymphoma were treated with an anti-canine CD20 CAR.113 Dogs serve as a good human disease model, as they develop similar cancers with respect to genetics, biology, treatments, and responses.113,140 In a case study of one dog, these investigators reported that a temporary stable disease status was achieved following three doses of CAR-mRNA T cells. Interestingly, the dog developed anti-mouse antibodies after repeated exposure to scFv of murine origin, similar to that in humans.141 This indicates that host compatibility is critical and that less immunogenic CAR designs are needed. Table 4Electroporation settings for T cells with chimeric antigen receptorsCell typeAntigen-CAR typeEP system (company)Type of pulseVoltage (V)Capacitance (μF)Time (ms)EP gap (mm)EP buffer (μL)Amount of mRNA (μg)Cell number (×106 cells)Cell concentration (×106 cells/mL)% CAR expression after EP (time point)ReferenceExpanded γδ and CD8 T cellsaMCSP-28zGene Pulser Xcell (Bio-Rad)SW500n.a.54ND15n.a.1NDHarrer et al.98PBMCaCD3-28BBzECM830 (BTX)SWNDn.a.ND2100ND10–30100–300>90%Liu et al.142Expanded T cellsahCD19-z, acCD20-zElectro Square Porator (ND)SW500n.a.0.722002020100>90%Panjwani et al.113Expanded CD25-depleted T cellsaCD19-CD28/OX40zECM830 (BTX)SW500n.a.24300–7000.1–150 μg/mL30–701094.1% (18–20 h)Almasbak et al.114Stimulated T cellsaCD19-BBznucleofector T cell transfection kit (Lonza)/ECM830 (BTX)ND (T23)/SWNDNDNDND1001055NDFoster et al.115Expanded T cellsaCD19-BBz, aCD19-28zECM830 (BTX)SWNDn.a.ND21001/5/1010–30100–30094% (18 h)Liu et al.116Expanded T cellsaFRa-27z, aCD19-27zECM830 (BTX)SW500n.a.0.721001010100>95%Schutsky et al.117Stimulated T cellsaCD19-BBzECM830 (BTX)SWNDn.a.ND21001010–30100–30099%Barrett et al.118Expanded T cellsaCD19-BBz, aGD2-BBzECM830 (BTX)SWNDn.a.ND21001010–30100–300>95%Singh et al.119Stimulated T cellsaCD19-BBz, aMeso-BBzECM830 (BTX)SWNDn.a.ND21001010–30100–300>99%Barrett et al.120Expanded T cellsaCD19-zECM830 (BTX)SWNDn.a.ND210010550NDKunii et al.121Expanded T cellsaCD19-BBzECM830 (BTX)SWNDNDND210010010100NDBillingsley et al.122Stimulated T cellsaCD33-BBzECM830 (BTX)SWNDn.a.ND21001010–30100–300>90%Kenderian et al.145Expanded T cellsaCD37-BBzECM830 (BTX)SW500n.a.24ND100 μg/mLn.a.62.5>90% (18 h)Koksal et al.143Expanded CD8 T cellsaBCMA-28zNDNDNDNDNDNDNDNDNDND72% (4 h)Lin et al.222Stimulated T cellsaMeso-z, aMeso-28z, aMeso-BBzECM830 (BTX)/Maxcyte (Maxcyte)NDNDNDND2/OC-400 Chamber100–20010–20100100–300>95%Zhao et al.126PBL or PBMCaMeso-BBzGT System (Maxcyte)NDNDNDNDNDND200 μg/mLn.a.500>35% of CD3+Hung et al.127Expanded CD4 or CD8 T cellsaMCSP-z, aMCSP-28zGene Pulser Xcell (Bio-Rad)SW500n.a.54100–600150 μg/mL14–84140>95% (4 h)Krug et al.128CD8 T cellsaMCSP-28zGene Pulser Xcell (Bio-Rad)SW500n.a.54ND10NDND85% (8 h)Uslu et al.129Expanded T cellsaMCSP-28zGene Pulser Xcell (Bio-Rad)SW500n.a.54NDNDNDND∼80%Simon et al.130CD4 or CD8 T cellsaMCSP-28z, CEA-28zGene Pulser Xcell (Bio-Rad)SW500n.a.54NDNDNDNDNDSimon et al.131Expanded T cellsaMCSP-28zGene Pulser Xcell (Bio-Rad)SW500n.a.54ND150 μg/mLn.a.15088% (8 h)Wiesinger et al.132Stimulated PBLaHER2-28zECM830 (BTX)SW400n.a.0.521001011090%–99% (16 h)Yoon et al.133Stimulated PBLaHER2-28zECM830 (BTX)SW400n.a.0.5210010110.>98%Lee et al.134CD4 and CD8 T cellsaHER2, aCEAGene Pulser Xcell (Bio-Rad)SW500n.a.54100–600150 μg/mL14–84140ErbB2: 83.0%/89.7% (4 h)CEA: 82.1%/81.4% (4 h)Birkholz et al.135Expanded T cellsaFRb-z, aFRb-28zECM830 (BTX)SW500n.a.0.7NDND1010n.a.highLynn et al.144Expanded T cellsaEGFR-28zAmaxa 4D Nucleofector (Lonza)DQ-115NDNDNDND200320100CD8+ T cells: ∼60% (24 h)CD4+ T cells: ∼30% (24 h)Caruso et al.146Expanded CD4 or CD8 T cellsNKG2D-28zNDNDNDNDNDND10010≤6100highLehner et al.136Expanded γδ T cellsaNKG2D-zNEPA21 (Nepa Gene)ND240n.a.42NDNDNDND96%Ang et al.137Expanded T cellsaNKG2D-z, aNKG2D-27z,aNKG2D-28z, aNKG2D-28BBzNEPA21 (Nepa Gene)ND240n.a.421005110>92% (24 h)Li et al.138Expanded T cellsaEpCAM-28BBzNEPA21 (Nepa Gene)ND240n.a.4220020NDND68.5%Ang et al.223Expanded T cellsDMF5 TCR-28z,Radium-1 TCR-28zECM830 (BTX)SW500n.a.24ND100 μg/mLn.a.70high (8 h)Walseng et al.147aCEA, anti-carcinoembryonic antigen; aEpCAM, anti-epithelial cell adhesion molecule; aFRa, anti-folate receptor alpha; aHER2, anti-human epidermal growth factor receptor 2; aMCSP, anti-melanoma-associated chondroitin sulfate proteoglycan; aMeso, anti-mesothelin; CAR, chimeric antigen receptor; DMF5, MART-126-35 specific; EGFR, epidermal growth factor receptor; EP, electroporation; gp100, glycoprotein 100; h, hours; mRNA, messenger RNA; n.a., not applicable; n.d., no data; PBL, peripheral blood lymphocytes; PBMC, peripheral blood mononuclear cells; Radium-1, specific to frameshift mutation in TGF beta Receptor 2; TCR, T cell receptor; -27z, CD27-CD3ζ signaling domain; -28BBz, CD28-4-1BB-CD3ζ signaling domain; -28z, CD28-CD3ζ signaling domain; -BBz, 4-1BB-CD3ζ signaling domain; -z, CD3ζ signaling domain. Electroporation settings for T cells with chimeric antigen receptors aCEA, anti-carcinoembryonic antigen; aEpCAM, anti-epithelial cell adhesion molecule; aFRa, anti-folate receptor alpha; aHER2, anti-human epidermal growth factor receptor 2; aMCSP, anti-melanoma-associated chondroitin sulfate proteoglycan; aMeso, anti-mesothelin; CAR, chimeric antigen receptor; DMF5, MART-126-35 specific; EGFR, epidermal growth factor receptor; EP, electroporation; gp100, glycoprotein 100; h, hours; mRNA, messenger RNA; n.a., not applicable; n.d., no data; PBL, peripheral blood lymphocytes; PBMC, peripheral blood mononuclear cells; Radium-1, specific to frameshift mutation in TGF beta Receptor 2; TCR, T cell receptor; -27z, CD27-CD3ζ signaling domain; -28BBz, CD28-4-1BB-CD3ζ signaling domain; -28z, CD28-CD3ζ signaling domain; -BBz, 4-1BB-CD3ζ signaling domain; -z, CD3ζ signaling domain. It could be argued that in practice, CAR persistence is needed for favorable clinical outcomes and, therefore, CAR-mRNA electroporation does not represent a real therapeutic alternative. Incorporating multiple doses of CAR-mRNA T cells (or any other type of antigen-specific immune receptor) into the treatment schedule was expected to overcome the limited persistence shown by these cells.139 Although early reports indicated varying CAR-T-cell doses and frequency of injections administered, all achieved significant tumor regression and delayed disease progression.126,133,134 Most subsequent studies opted for administering CAR-mRNA T cells weekly, corresponding to the duration of transient expression of the receptor.113,116,117,127 Regardless of the transient persistence of CAR-mRNA T cells, multiple preclinical studies have demonstrated that the overall survival of tumor-bearing mice was significantly improved following a single dose of CAR-mRNA T cells.116,118,119,127,128,142,143 Furthermore, it was found that complete ablation of previously administered CAR-T cells using cyclophosphamide combined with multiple decreasing IV doses was most effective in leukemia and disseminated neuroblastoma mouse models.119,120 However, in a neuroblastoma model, CAR-mRNA T cells controlled the disease only temporarily, whereas a majority of the controls treated with lentiviral CAR-T cells went into remission.119 Two other studies also combined cyclophosphamide lymphodepletion with either a CD30-targeted CAR or a FRβ-targeted CAR.144,145 Neither was able to induce complete remission, and moreover, the CAR-mRNA T cell therapy was inferior to its respective lentiviral counterpart.144 These outcomes may be attributed to minimal migration and infiltration by CAR-mRNA T cells due to a short life-span combined with receptor internalization, following T cell stimulation.119,146 Therefore, the anti-tumor effect of CAR-mRNA T cells may be maximized via intra-tumoral administering, as seen with TCR-mRNA T cells.119,146 Furthermore, this approach may reduce on-target off-tumor toxicity when targeting antigens that exhibit considerable expression on normal cells as well.146 Similar to TCR-mRNA, most studies using CAR-mRNA have focused on modifying activated or expanded conventional peripheral blood lymphocytes (PBLs). However, γδ T cells are also important for CAR engineering.98,137 Allogeneic CAR-T-cell therapy using γδ T cells isolated from healthy donors is possible due to the anti-tumor activity and MHC-independent antigen recognition capability of γδ T cells. Comparable to CAR-modified CD8 T cells, MCSP-CAR mRNA-transfected γδ T cells specifically lyse antigen-positive target cells, while secreting fewer proinflammatory cytokines, thereby reducing the risk of CRS.98 In addition, anti-tumor cytotoxicity mediated through endogenous receptors was not affected by the introduction of a CAR, as demonstrated by the strong killing capacity against the MHC-negative and antigen-deficient Daudi cell line in vitro. Apart from the CAR construct, several other enhancements have also been studied in the context of CAR-T cells. TETARs, previously evaluated in T cells transfected with two TCRs, were further explored via simultaneous electroporation of mRNAs encoding a gp100-specific TCR and MCSP-specific CAR.129 When challenged in vitro with tumor cells carrying both antigens, T cells expressing both receptors produced more cytokines compared to that of a balanced mix of T cells with a single receptor. This combination of receptors also exerted a synergistic effect on cytolytic capacity. Interestingly, when TCR and CAR were introduced via lentiviral transduction and mRNA electroporation, respectively, the addition of CAR to TETARs displayed a minor beneficial killing effect compared to that of the TCR-only cells.130 In an effort to combine the benefits of a TCR and CAR into a single molecule, Wälchli et al. created a TCR-CAR by fusing the extracellular domain of TCR chains to the intracellular portion of a second-generation CAR.147 In contrast to the traditional concept of CARs, TCR-CAR allows targeting of peptides presented by the MHC complex, while maintaining CAR-like (co)stimulation of T cells. Furthermore, introduction of TCR-CAR mRNA into non-T cells renders them pMHC restricted. Transient modification of cells with CARs can also be used in other applications. For instance, Liu et al. established a novel expansion method by introducing anti-CD3ε CAR mRNA into peripheral blood mononuclear cells (PBMCs) to generate OKT3-28BB T cells.142 Compared to T cells expanded with CD3/CD28 Dynabeads, OKT3/IL-2 expansion generates a more differentiated (effector memory) T cell population, with decreased migratory and proliferative capacity but with increased direct tumor control. Additional co-electroporation of costimulatory molecule ligands CD86 and 4-1BB ligand (4-1BBL) in OKT3-28BB T cells results in a more naive phenotype similar to CD3/CD28 expanded T cells, while maintaining in vitro tumor killing capacity similar to that of more differentiated OKT3/IL-2 expanded T cells that are generated when virally transduced with an anti-mesothelin CAR (aMeso CAR).142 However, subsequent in vivo ovarian and leukemia mouse models showed that OKT3-28BB-expanded aMeso CAR-T cells were inferior to CD3/CD28-expanded aMeso CAR-T cells. mRNA-based CAR-T cell therapies have not yet achieved preclinical efficiencies approaching that of viral CAR-T cells. Nonetheless, these significantly contribute to immunotherapy in several ways. Cheaper and less complex release testing and manufacturing of clinical grade mRNA compared to that of viral vectors facilitate more rapid clinical translation for toxicity testing.120,127,148 The combination of time-limited adverse events and short-term cytotoxicity has prompted investigators to suggest the use of T cells equipped with a potent but toxic CAR as “induction therapy,” to be followed by stably transduced CAR-T cells as “consolidation therapy.”126 This hit-and-run strategy may also prove useful for inducing epitope spreading, which is associated with favorable clinical outcome135 and bystander destruction of antigen-negative tumor cells, avoiding immune escape.116 Clinical studies of mRNA CAR-T cells are limited to only a few early-phase clinical trials, primarily in solid tumors (clinicaltrials.gov identifiers: NCT01355965, NCT01897415, NCT03060356, NCT03608618, and NCT01837602) and advanced cancers (clinicaltrials.gov identifiers: NCT05302037 and NCT04981691), but they have also been explored in hematological malignancies (clinicaltrials.gov identifiers: NCT02277522, NCT02624258, NCT02623582, and NCT03448978) (Table 3). Beatty et al. were the first to report the safe and effective use of aMeso CAR-mRNA T cells without prior lymphodepletion.149,150 Consistent with the transient nature of the cell product, CAR transcripts are detectable for up to 3 days, and toxicity is limited and temporary. Notably, one patient from the same study went into anaphylactic shock after the third dose of aMeso CAR-T cells was administered, which was caused by a humoral response against the murine scFv of the CAR, leading to the protocol for administering CAR-T cells being adjusted.141 This patient showed a partial response after only three injections, but the disease progressed after 6 months.149 Importantly, CAR-mRNA T cells were able to traffic to and infiltrate the tumor, while also inducing epitope spreading.149,150 Similarly, intra-tumoral injection of anti-cMet CAR-T cells into breast tumors demonstrated extravasation into the bloodstream without any signs of off-tumor toxicity.151 Another phase I trial by the same team will investigate the safety of IV injection of these CAR-T cells. Svoboda et al. studied five patients with classical Hodgkin lymphoma who were treated with six injections of CD19-targeted CAR-T cells.152 Two patients showed a clinical response after 1 month, which is believed to be linked to the persistence of CAR-T cells following injection. Although these responses were also transient, these could be restored by additional treatment such as anti-PD-1 therapy or autologous hematopoietic stem cell transplantation (HSCT).152 Notably, these early-phase clinical trials were limited to only a few repeated injections of CAR-mRNA T cells. Therefore, future investigations involving more extensive administering schedules, which require a considerable amount of autologous T cells, are needed. Considerations regarding a clinical expansion protocol specifically for CAR-mRNA T cells were recently investigated.132,153,154 Adjuvant gene transfer Taking advantage of the flexibility that mRNA electroporation offers for simultaneous introduction of multiple genes into T cells, some studies have focused on adjuvants, either alone or together with immune receptors to redirect T cell specificity. Kunii et al. demonstrated that mRNA co-electroporation of a linker for activation of T cells (LAT) variant that is resistant to ubiquitination (2KR LAT) and a CAR or TCR may improve downstream signaling, which increases the cytotoxic capacity of CD8 T cells and promotes the polarization of Th1 CD4 T cells.121 A follow-up study using TCR-modified 2KR LAT transgenic mice revealed T cells with a more differentiated phenotype, which however failed to confer a beneficial effect, compared to that of wild-type LAT.155 As a less differentiated phenotype correlates with a reduced clinical effect,142 temporary modification may not only be safer but also improve efficacy. To the best of our knowledge, Lee et al. were the first to report on fourth-generation CAR-T cells that were modified to express both IL-2 and an HER2-specific CAR (CAR/IL-2).134 When injected intratumorally into established subcutaneous ovarian cancer, CAR/IL-2 T cells were slightly better at controlling tumor growth than single modified CAR-mRNA or IL-2-mRNA T cells, which are mediated by the recruitment of NK cells to the tumor site. As T cell homing defects have been observed in multiple cases of cancer,156 T cells were co-transfected with mRNA for chemokine receptors, such as the C-X-C motif chemokine receptor (CXCR) 2, also called IL-8 receptor,157,158 and C-C chemokine receptor type (CCR) 7 or CXCR4.114,157,158 IL-8, which is secreted by multiple types of cancer, plays an important role in tumor escape. Many T cells do not express the receptor for IL-8 and are incapable of trafficking toward IL-8-secreting tumor cells. Thus, this approach may be helpful for malignancies, such as brain tumors, in which immune cell trafficking is limited. Gross et al. described mRNA-engineered T cells with caTLR4, which circumvent the need for Toll-like receptor (TLR) 4 ligand binding.159 CaTLR4-engineered T cells show an enhanced anti-tumor profile with an increase in the secretion of different cytokines (including IFN-γ) as well as expression of T cell activation markers and killing of melanoma cells. Interleukins, such as IL-2, IL-12, and IL-15, have been proven to be beneficial in cancer immunotherapy. However, injection of soluble cytokines, or the stable IL-12 expression in some cases, led to unacceptable toxicities in clinical trials.160 In vivo analysis of T cells electroporated with mRNA encoding single-chain IL-12, either alone or in combination with a 4-1BB ligand, revealed that intra-tumoral injection of engineered cells enabled rejection of local and distant tumors,161 while limiting the duration of potential adverse toxicities due to its transient expression. T cells have also been transfected with cytokine-encoding mRNAs to induce membrane presentation and improve the growth and functionality of T cells, in comparison to their soluble counterparts. Co-transfection of caTLR4 and cytokines such as IL-2, IL-12, or IL-15 further stimulated T cell functionality compared to that of caTLR4 alone, although each of the cytokines affects functionality differently.162 For example, caTLR4 combined with IL-2, or IL-12, acts synergistically to potentiate the secretion of effector factors, while a combination of caTLR4 and IL-15 increases the expression of activation markers. In a similar fashion, T cells have been mRNA-engineered with constitutively active CD40 (caCD40), a member of the type 1 TNFR family mainly expressed by professional APCs.163 As for caTLR4, activation of CD40 is mediated by engagement with CD40L. However, caCD40 expression may be achieved by homo-oligomerization of the CD40 signaling domain.163 Simultaneous transfection with caCD40 and caTLR4 further improved T cell activity compared to that of either of the two receptors alone.163 Combinations of these receptors and the cytokines mentioned above promote the secretion of IFN-γ and the upregulation of T cell activation markers by mRNA-engineered T cells,164 confirming that the addition of multiple adjuvants is beneficial. Importantly, enhanced T cell IFN-γ production observed by the aforementioned studies159,162,163,164 often correlates with clinical efficacy and tumor regression. However, it has yet to be demonstrated whether co-transfection of TCR-mRNA or CAR-mRNA with these or other costimulatory molecules would have an impact on engineered T cells. Finally, T cells can also act as carriers for secreted anti-cancer molecules. For example, T cells transfected with mRNA with a cytotoxic immunotoxin from a truncated version of Pseudomonas exotoxin A have been used to attack neovasculature of tumors.165 mRNA electroporation of natural killer cells NK cells are components of the innate immune system and make up 5%–15% of peripheral blood lymphocytes.166 They are mainly found in circulating blood and hematopoietic tissues but migrate to sites of infection or tumor growth after activation. NK cells exert both cytotoxic and regulatory effects and are involved in tumor surveillance without depending on specific antigens. Due to these properties, NK cells are extensively used in cancer immunotherapy. In an effort to direct the specificity of NK cells toward TAAs, these cells have been primarily engineered with CARs via mRNA electroporation (Table 5). Early NK-CARs targeted CD19 and CD20 for their use in B cell malignancies, but newer targets like CD70 (colorectal cancer),167 MCAM and EphA2 (sarcoma),168,169 and BCMA (multiple myeloma)170 are now being explored as well. Table 5Electroporation settings for natural killer cellsCell typeGene(s)EP system (company)Type of pulseVoltage (V)Capacitance (μF)Time (ms)EP gap (mm)EP buffer (μL)Amount of mRNA (μg)Cell number (×106 cells)Cell concentration (×106 cells/mL)% protein expression (time point)ReferenceExpanded NK cellsaCD20-BBz CARAmaxa nucleofector II (Lonza)Program U-001NDNDNDND10080-100 μg/mL6–860–8094.1% (20 h)Chu et al.176, Chu et al.177Stimulated NK cellsaCD19-28/OX40z CARaCD19-BBz CARECM830 (BTX)SW500ND24400100 μg/mLND10–5080%–90% (24 h)Oei et al.179Expanded NK cellsCCR7, CD16, CD34MaxCyte GT (MaxCyte)program for NK cells proprietary to MaxCyteNDNDNDOC-1001001 μg/106 cellsNDND∼90% (24 h)Carlsten et al.184Expanded NK cellsCXCR4R334XCXCR4WTMaxCyte GT (MaxCyte)NK2-OCNDNDNDNDND4 μg/106 cellsND1–2×106 cells/10 μLpeak at 4–8 hLevy et al.185Expanded NK cellsCXCR1 aNKG2DL-z CARaNKG2DL-28z CARaNKG2DL-28BBz CARNEPA21 (Nepa Gene)ND240n.a.421005 μg10ND95% (24 h)Ng et al.183Expanded NK cellsCCR7MaxCyte GT (MaxCyte)NK2-OCNDNDNDNDND0.5, 1, 2, 4, or 8 μg/106 cellsND1–2 × 106 cells/10 μLpeak at 8 hLevy et al.187Unstimulated and expanded NK cellsaCD19-BBz CARMaxCyte GT (MaxCyte)unstimulated NK#1expanded NK#3NDNDNDMaxCyte processing chamberND100 μg/mLND100–300∼60% (ND)Li et al.224Unstimulated and expanded NK cellsaCD19-BBz CARMaxCyte GT (MaxCyte)Static NK#2NDNDNDND50100–200 mg/mL10–15200–300unstimulated: 40.3% (24 h)expanded: 61.3% (24 h)Shimasaki et al.225Unstimulated and expanded NK cellsaCD19-BBz CARMaxCyte GT (MaxCyte)Static NK#2NDNDNDND50150–200 μg/mL10–15NDunstimulated: 18.1%–59.2% (24 h)expanded: 28.2%–92.4% (24 h)Shimasaki et al.180Expanded NK cellsaCD20-BBz CARAmaxa nucleofector II (Lonza)Program U-001NDNDNDND10080–100 μg/mL6–8n.a.95% (24 h)Chu et al.181Expanded NK cells from cord bloodGFPGene Pulser II (Bio-Rad)ND250300300300150300n.a.NDNDNDNDND0.3%10%0.4% (24 h)Boissel et al.188Amaxa nucleofector (Lonza)Program U-01NDNDNDNDNDNDNDND52.5% (24 h)NK-92GFP, αCD19-z CARGene Pulser II (Bio-Rad)ND300150ND425040 μg/mL (GFP)120 μg/mL (CAR)2876% GFP47.2% CAR (24 h)Boissel et al.192NK-92GFP aCD19-BBz CARaCD20-BBz CARGene Pulser II (Bio-Rad)ND300150NDND25040 μg/mL2855.8% (24 h)Boissel et al.193Expanded NK cellsMAGT1MaxCyte (not further defined)Program NK_3_OCNDNDNDNDND400 μg/mL500NDNDBrault et al.226Expanded NK cellsCXCR4, aBCMAz CAR, mGFPNEPA21 (Nepa Gene), Agilepulse (BTX)NDcondition 1: 240, condition 2: 800NDcondition 1: 4, condition 2: 1condition 1: 2, condition 2: 4condition 1: 200, condition 2: 40010 μgcondition 1: 10, condition 2: 100condition 1: 50,condition 2: 25091% mGFP (48 h)91% αBCMAz (48 h)92% αBCMAp (48 h)Ng et al.186NK-92CD19-BBz CAR, BCMA-BBz CARGene Pulser Xcell (Bio-Rad)SW300ND12420050 μg/mL (one CAR) or 100 μg/mL (two CARs)2510076% CD19 CAR58.1% BCMA CAR88.1% CD19+BCMA CARRoex et al.170Expanded NK cellsPD-1 mRNAGene Pulser XcellSW500ND5NDNDND20–4040–80NDVersteven et al.211Expanded NK cellsaMCAM-BBz CARMaxCyte GT (MaxCyte)NDNDNDNDNDND105ND53% (48 h)Luo et al.168Expanded NK cells from cord bloodaCD19-BBz, aCD20-BBzCeletrix Electroporation (Celetrix Corporation)ND640ND30ND1203 μg (one CAR) or 6 μg (two CARs)1893.1% CD19 CAR90.5% CD20 CAR86.4% CD19-CD20 CARYang et al.189Expanded NK cells from cord blood and from PBMCaEphA2-28z CARMaxCyte STx (MaxCyte)Program NK-2, NK-3NDNDNDNDND15 pmol/million cells or 200 μg/mLNDND70%–80%Lam et al.169NK-92CD70-BBz CAR, CD70-BBz-IL-15Gene Pulser Xcell (Bio-Rad)ED300ND124200100 μg/mL5–2525–12588.5%Van den Eynde et al.167Expanded NK cellsaSLAMF7-28z CAR, aAnnexin A2-28z CAR, aCD33-28z CAR4D-Nucleofector X (Lonza)Program CM-137NDNDND20 μL cuvetteNDND1ND60% (6 h), 55% (24 h)Wang et al.227Expanded NK cellsaNKG2D-z CARNEON Transfection System (Invitrogen)ND1600ND10NDNDNDNDNDNDLook et al.228BCMA, B cell maturation antigen; CAR, chimeric antigen receptor; CCR7, C-C chemokine receptor type 7; CXCR(number), C-X-C chemokine receptor type (number); DAP12, DNAX-activating protein of 12 kDa; EP, electroporation; EphA2, ephrin type-A receptor-2; GFP, green fluorescent protein; h, hours; MAGT1, magnesium transporter 1; MCAM, melanoma cell adhesion molecule, n.a., not applicable; n.d., no data; NK, natural killer; NKG2D, natural killer group 2D; mRNA, messenger RNA; ROR1, receptor tyrosine kinase-like orphan receptor 1; SLAMF7, signaling lymphocytic activation molecule family member 7; SW, square wave; −28z, CD28-CD3ζ signaling domain;-28BBz, CD28-4-1BB-CD3ζ signaling domain; −28/OX40z, CD28-OX40-CD3ζ signaling domain; -BBz, 4-1BB-CD3ζ signaling domain; -z, CD3ζ signaling domain. Electroporation settings for natural killer cells BCMA, B cell maturation antigen; CAR, chimeric antigen receptor; CCR7, C-C chemokine receptor type 7; CXCR(number), C-X-C chemokine receptor type (number); DAP12, DNAX-activating protein of 12 kDa; EP, electroporation; EphA2, ephrin type-A receptor-2; GFP, green fluorescent protein; h, hours; MAGT1, magnesium transporter 1; MCAM, melanoma cell adhesion molecule, n.a., not applicable; n.d., no data; NK, natural killer; NKG2D, natural killer group 2D; mRNA, messenger RNA; ROR1, receptor tyrosine kinase-like orphan receptor 1; SLAMF7, signaling lymphocytic activation molecule family member 7; SW, square wave; −28z, CD28-CD3ζ signaling domain;-28BBz, CD28-4-1BB-CD3ζ signaling domain; −28/OX40z, CD28-OX40-CD3ζ signaling domain; -BBz, 4-1BB-CD3ζ signaling domain; -z, CD3ζ signaling domain. Prior to the above process, the low frequency of NK cells in peripheral blood has to be overcome, and therefore NK cells are expanded ex vivo until numbers sufficient for adoptive transfer are reached.171 NK cells from bulk PBMCs or previously isolated NK cells can be expanded using autologous feeder cells in combination with anti-CD16 antibodies,172 under cell-free conditions via addition of exogenous proliferation, maturation, and survival-inducing common gamma chain cytokines, such as IL-15 and IL-21,173 or using artificial APCs modified to express membrane-bound cytokines and 4-1BBL.174,175,176,177 IL-15, in particular, induces NK cell maturation and provides support for NK cell survival in peripheral lymphoid organs.178 A protocol, which uses IL-15 to stimulate primary NK cells prior to electroporation with second- and third-generation anti-CD19 CAR-mRNAs, has demonstrated that the status of differentiation plays an important role in the production of effective CAR-engineered NK cells.179 Compared with non-stimulated cells, optimal CAR expression is obtained after incubating the cells with IL-15 for 3 days. Moreover, the killing capacity of engineered NK cells toward CD19-positive targets is specifically enhanced by the presence of the anti-CD19 CAR. A similar effect was seen by another group who developed a fourth-generation CD70-CAR NK therapy, integrating an IL-15 cytokine cassette into the CAR sequence. IL-15 stimulation resulted in improved potency of CD70-CAR NK cells by upregulating CAR expression and increasing secretion of pro-inflammatory cytokines like interferon gamma (INF-γ) and TNF-α, eventually resulting in enhanced anti-tumor effect in mice.167 Specific cytotoxic activity against acute lymphoblastic leukemia and B-lineage chronic lymphocytic leukemia (B-CLL) cells was achieved by introducing a third-generation anti-CD19 CAR into both types of NK cells. However, CAR expression persisted for only up to 3 days, whereas other studies have reported longer CAR expression kinetics, of up to 6 days following transfection.176,179 In an in vivo follow-up study, expanded and anti-CD19 CAR-mRNA-electroporated NK cells were injected intravenously or intraperitoneally into immunodeficient mice engrafted with CD19-positive human B-lineage acute lymphoblastic leukemia (B-ALL) cells.180 CAR-modified NK cells administered by either route significantly reduced the leukemia burden compared to that of the control NK cells. CD20 antigen was also targeted using CAR-engineered NK cells, as a treatment against CD20-positive B cell leukemia and non-Hodgkin lymphoma (NHL) cells.176 Although CAR-electroporated expanded peripheral blood NK cells are not influenced by activating or inhibitory receptors, these exhibited enhanced in vitro toxicity and cytokine production. Moreover, the tumor burden in NOD scid gamma (NSG) mice xenografted with rituximab-sensitive or rituximab-resistant Burkitt lymphoma cells was significantly reduced after being administered thrice with CAR-engineered NK cells, which, in turn, correlated with longer survival compared to that of untreated mice. However, most of the xenografted mice ultimately succumbed to the disease and died. In a follow-up analysis,181 the investigators showed that combining anti-CD20 CAR-NK cells with the histone deacetylase inhibitor romidepsin further enhanced the cytotoxic capacity of CAR-NK cells against Burkitt lymphoma cells, both in vitro and in vivo. The synergistic effect of the combinatorial treatment also prolonged the survival rate of the xenografted NSG mice, which provides a basis for the evaluation of other combinatorial approaches. Alternative receptor designs have also been explored in NK cells. One such strategy involves replacing the conventional scFv recognition domain with the extracellular domain of NKG2D, an approach that has recently been evaluated in a clinical trial for colorectal cancer (NCT03415100; Table 3).182 First, the investigators used a xenograft mouse model to compare the efficacy of an NKG2D-CAR carrying a conventional CD3ζ intracellular domain (NKG2Dζ) to that of a CAR with a DNAX activation protein of 12 kDa (DAP12) signaling domain (NKG2Dp). NKG2Dp was superior to NKG2Dζ in terms of antitumor activity against NKG2D-ligand-positive tumor cells.182 Subsequently, the NKG2Dp-CAR was used in patient-derived or haploidentical family-donor-derived NK cells in the clinical trial, demonstrating that multiple rounds of CAR-mRNA-electroporated NK cells were clinically effective in controlling malignant ascites.182 Similar to T cells, NK cells have been reprogrammed with mRNA using homing chemokine receptors, such as CXCR1,183 CCR7,184 and CXCR4.185,186 In a xenograft mouse model, co-electroporation with CXCR1-mRNA and CAR-mRNAs, the latter being composed of the extracellular domain of NKG2D against tumor-associated NKG2D ligands, redirected NK cell infiltration toward human tumor sites without affecting CAR-mediated killing.183 CCR7, which is naturally present only in a small subset of NK cells, induces NK cell migration toward secondary lymphoid tissues, such as lymph nodes, where hematological tumor cells may be found. However, CCR7 expression is lost upon expansion ex vivo. Introduction of CCR7 also significantly induces in vitro migration of NK cells toward the chemokine (C-C motif) ligand, (CCL)19.184 As occurs with native expression of CCR7 in NK cells, exposure to increasing doses of CCL19 reduces CCR7 expression in the engineered NK cells, homing these cells to CCL19-rich sites. In regard to CXCR4, NK cells modified with a gain-of-function variant of this receptor demonstrated improved migration to the bone marrow.185 This demonstrated that the benefits of combining mRNAs encoding chemokine and TAA-specific receptors observed in T cells may also apply to NK cells. In addition, transfection of NK cells isolated from donors expressing the Fc gamma receptor IIIa (CD16)-158F/F homozygous variant with mRNA encoding the high-affinity antibody-binding receptor variant CD16-158V induces greater antibody-dependent cellular-cytotoxicity-mediated activity against rituximab-coated lymphoma cells.184 A detailed protocol for mRNA electroporation of primary NK cells, including recommendations for its optimization, is available.187 Due to the scarcity and low functionality of peripheral blood NK cells in patients, considerable efforts have been directed toward establishing alternative sources of NK cells. One promising candidate for gene transfer via mRNA electroporation are cord blood (CB)-derived NK cells.188 In terms of cytotoxic activity and proliferation, the characteristics of these cells are similar to those of peripheral blood NK cells. Cord blood contains a higher percentage of NK cells (15%–30%) compared to their peripheral blood counterparts189; however CB-derived NK cells still must be expanded ex vivo in order to obtain sufficient amounts for modification. In this case, expansion of CB-derived NK cells can be accomplished using umbilical cord mesenchymal stem cells as feeder cells or with membrane-bound IL-21-transfected K562 feeder cells.169,189 Alternatively, NK cell lines have been established via human clonal NK cell lymphomas.190 The NK-92 cell line, established by Gong et al.191 is the most extensively used NK cell line. Due to the excellent anti-tumor cytotoxic properties of this cell line, it has been used in both preclinical and clinical studies to evaluate CARs.167,170,190 Boissel et al.192 compared the electroporation efficiencies of cDNA and mRNA for anti-CD19 CAR in NK-92 cells. The mRNA-electroporated NK-92 cells expressed the receptor more efficiently than the cDNA-electroporated counterparts with minimal loss of cell viability. Moreover, NK-92 cells transfected with anti-CD19 CAR-mRNA killed CD19-positive B-ALL cell lines that were previously NK-92 resistant, as well as primary B-CLL cells. In a similar study, these investigators compared the transfection efficiency of lentiviral vectors with that of mRNA electroporation in NK-92 cells. They used two CARs targeting either CD19-positive or CD20-positive cells in B-CLL cells. Their results revealed significantly higher expression levels of both CD19 and CD20 CAR in NK-92 cells electroporated with CD19-CAR and CD20-CAR mRNAs compared to those transformed via lentiviral transduction. The differences in CAR expression also correlated with enhanced killing of primary B-CLL cells.193 Demonstrating the feasibility of using multiple CARs to address antigen loss in NK cell therapy, our group engineered NK-92 cells co-expressing both CD19- and BCMA-targeting CARs. These dual-CAR NK-92 cells showed significantly enhanced cytotoxicity against B cell malignancies compared to NK-92 cells expressing either CD19- or BCMA-specific CARs alone.170 mRNA electroporation of B cells B cells have also been evaluated over the past two decades as potential professional APCs for tumor immunology (Table 6). Similar to DCs, B cells express homing receptors, such as CD62L, CCR7, and CXCR4, which facilitate migration to secondary lymphoid organs and attract T cells chemotactically.194 In addition, ex vivo cultures of small amounts of starting material with CD40L and IL-4 allowed the production of a large number of licensed B cells (CD40-B cells) that highly expressed MHC and costimulatory molecules.195 Table 6Electroporation settings for B cellsCell typeGene(s)EP system (company)Type of pulseVoltage (V)Capacitance (μF)Time (ms)Gap (mm)Buffer (μL)Amount of mRNA (μg)Cell number (×106 cells)Cell concentration (×106cells/mL)% protein expression after EP (time point)ReferenceCD40-B cellsGFPTumor RNAmodified square-wave electroporator (Amaxa)SW (Pulse Program U08)NDNDNDND10022–2.5n.a.>80% GFP (24 h)Coughlin et al.195CD40-B cellsCDV-HAeGFPmodified square-wave electroporator (Amaxa)SW (Pulse Program U08)NDNDNDND10022–2.5n.a.86% eGFP (24 h)Mason et al.204CD40-B cellsSurvivinGFPTumor RNAmodified square-wave electroporator (Amaxa)SW (Pulse Program U08)NDNDNDND1002-5 (Survivin and GFP)2/10 (Tumor Rn.a.)2–2.5n.a.NDCoughlin et al.197LPS-B cellsCD40-B cellsEGFPCEAGene Pulser (BTX)SW300n.a.0.5220020n.a.5∼50% eGFP (24 h)Park et al.198CD40-B cellsCDVTumor RNAnucleofector device (Amaxa)Pulse program U08NDNDNDND<2502 (CDV)10 (Tumor Rn.a.)<520NDSorenmo et al.199CD40-B cellsdeltaLMP1ECM830 (BTX)SW350n.a.0.3524020n.a.25>70% (36 h)Demachi-Okamura et al.200CD40-B cellsTumor RNANDND300150NDND10022–2.5n.a.NDShen et al.201CpG-B cellsLPS-B cellsCD40-B cellsIL-12p35IL-12p40CD80OX40L4-1BBLActinOVAECM830 (BTX)SW340n.a.0.5220052n.a.IL-12p70: ∼17.5 ng/mLCD80: 95%OX40L: 95%4-1BBL: 90% (24 h)Lee et al.203IL-4/IL-21 B-cells8 different constructsGene Pulser Xcell (Bio-Rad)NDNDNDND42005 μg eGFP, 20 μg other constructs3–815–4087.8% eGFP (20–24 h)De Keersmaecker et al.20CD40-B cellsGFPNEPA21 (Nepa Gene)ND275 (4 pulses), 20(5 pulses)ND1 (4 pulses), 50 (5 pulses)230 or 100530 μL: 1.5–3 or 100 μL: 5–1050>90%Nardi et al.229Abbreviations: CDV, canine distemper virus; CDV-HA, canine distemper virus HA polypeptide; CEA, carcinoembryonic antigen; deltaLMP1, mutant latent membrane protein 1; eGFP, enhanced green fluorescent protein; EP, electroporation; GFP, green fluorescent protein; h, hours; IL-12, interleukin-12; LPS, lipopolysaccharide; mRNA, messenger RNA; n.a., not applicable; n.d., no data; OVA, ovalbumin; OX40L, OX40 ligand; SW, square wave; 4-1BBL, 4-1BB ligand. Electroporation settings for B cells Abbreviations: CDV, canine distemper virus; CDV-HA, canine distemper virus HA polypeptide; CEA, carcinoembryonic antigen; deltaLMP1, mutant latent membrane protein 1; eGFP, enhanced green fluorescent protein; EP, electroporation; GFP, green fluorescent protein; h, hours; IL-12, interleukin-12; LPS, lipopolysaccharide; mRNA, messenger RNA; n.a., not applicable; n.d., no data; OVA, ovalbumin; OX40L, OX40 ligand; SW, square wave; 4-1BBL, 4-1BB ligand. Preclinical evaluation has repeatedly demonstrated that CD40-B cells can be efficiently electroporated with TAA mRNA. Similar to DCs, mRNA-loaded activated B cells are capable of activating T cells directed against tumor-specific antigens, such as MART-1, survivin, CEA, latent membrane protein 1, and WT1 in an MHC-dependent manner, even using patient-derived cells.195,196,197,198,199,200,201 Despite the practical advantages associated with activated B cells, these cells have been shown to be inferior T cell stimulators compared to DCs.202,203 Simultaneous transfection of antigen and immune stimulatory molecules, such as OX40L, 4-1BBL, IL-12p35, and IL-12p40, can bring CD40-B cells on par with mature DCs in terms of inducing antigen-specific T cell responses in vitro. However, this could not be replicated in vivo.203 Currently, no in-human clinical trials are being conducted for mRNA-electroporated B cells. However, Sorenmo et al. have reported the first preclinical large animal trial in which mRNA-loaded CD40-B cells were used to treat dogs with NHL.199 They opted for whole tumor RNA instead of tumor-specific antigen RNA in order to allow for a polyclonal anti-tumor T cell response.204 Following remission induced via chemotherapy, 19 dogs were vaccinated on opposing flanks with CD40-B cells loaded with full autologous tumor RNA or canine distemper virus hemagglutinin as an immunological control.199 While vaccination with tumor RNA-loaded CD40-B cells did not improve relapse-free or overall survival after induction chemotherapy, it appeared to potentiate salvage therapy, with 4 of 10 relapsed dogs achieving durable second remissions. In addition, there were no long-term-treatment-related toxicities. These results, combined with the continuous development of GMP-compatible B cell activation and expansion methods,205 pave the way toward the first in-human clinical trials of mRNA/total RNA electroporated CD40-B cells. Concluding remarks Gene transfer via mRNA electroporation may be used to express (multiple) desirable proteins in immune cells. Technically, this has been achieved using a wide range of electroporation parameters and conditions. To support researchers new to the field, we compiled a summary table of recommended electroporation settings for each cell type (Table 7). These conditions can serve as practical starting points for designing and optimizing electroporation protocols. Table 7Suggested starting points for electroporation conditions by cell typeCell typeType of pulseVoltage (V)Time (ms)Gap (mm)Buffer (μL)Amount of mRNA (μg)Cell concentration (×106cells/mL)DCSW300–5000.5–14100–60010–205–30T cells (CAR)SW5005 ms for 4mm cuvette0.5 ms for 2mm cuvette2 or 410010100–300T cells (TCR)SW5005 ms for 4mm cuvette0.5 ms for 2mm cuvette2 or 42001025–80NK cellsSW300124100100 μg/mL8–300B cellsSW3000.521002–205–50 Suggested starting points for electroporation conditions by cell type On the forefront of mRNA electroporation are DCs, which can be engineered for a wide range of purposes. Although DCs are most often electroporated with TAA-mRNA to redirect the immune system toward a specific tumor antigen, these are also engineered to enhance functionality. As such, they can now be induced to interact with a larger variety of immune effector cells and display a more activated phenotype. In contrast to lymphocyte engineering, DCs are almost exclusively mRNA-engineered by means of electroporation rather than via transduction. The main reasons for this difference are the limited lifespan of DCs and their non-proliferating properties. This makes electroporation the most appropriate technique for DC engineering. Although this technique is well established for transfecting DCs, leading to multiple clinical trials for different types of cancer, it has not fully reached its potential as far as lymphocytes are concerned. Administering of immune receptors, such as TCRs and CARs, capable of recognizing tumor antigens, is the approach that is currently used for lymphocyte engineering. In this case, researchers tend to apply more permanent approaches, such as viral transduction or transposon systems, to ensure that the cells will express the protein of interest throughout their lifespan. This conclusion applies to both T cells and NK cells. The lack of clinical trials using TCR-mRNA-electroporated lymphocytes, except for two minor trials, indicate that indeed the balance remains in favor of stable methods of lymphocyte engineering. In general CAR-engineered lymphocytes are favored slightly more than TCR engineering, although mRNA-based CAR-T or CAR-NK cell therapies have not yet achieved (pre)clinical efficiencies seen in virally produced CAR-T/CAR-NK cells. To date, the most favorable responses reported for these mRNA-based therapies have primarily been limited to stable disease in a subset of patients (Table 3). However, mRNA technology has proven to be flexible, allowing for rapid validation of the many iterations required to optimize TAA-specific TCR discovery as well as CAR design. The flexibility that mRNA electroporation offers is also highlighted by the possibility of multiplexing different mRNAs, as well as siRNAs for gene silencing or guide RNAs using the CRISPR/Cas system in targeted genome editing.206 In contrast to viral vectors, CRISPR/Cas-mediated knockin, transposon systems, and plasmid DNA transfection, transient gene expression linked to the natural decay of introduced mRNA provides an accurate system that can be utilized to regulate the synthesis of transgenic proteins. Similarly, tight control of transgenic cell dose in patients is possible via repeated administering of mRNA-electroporated cells. Considering the costs related to repeat administering, mRNA transfection is a less costly cell engineering platform due to the limited laboratory requirements and equipment needed, as well as the less cumbersome regulatory aspects involved in introducing it into a clinical environment compared to that of other methods. In terms of safety, viral transduction and non-viral stable genetic modification (e.g., transposons) are associated with the possibility of insertional mutagenesis caused by random integration of genetic material into the genome of the modified cell. Although this risk in principle is theoretical and has not been reported to date, potential concerns should not be dismissed. In this regard, mRNA electroporation offers a safer alternative. Studies with CAR-T cells have shown that, even though this therapy may cause severe adverse effects, the transient nature of expression involved causes less damage to patients than virally transduced T cells, which persist and exert a greater negative impact by continuing to damage patients for longer periods. In order to reduce this, additional safety mechanisms such as suicide genes should be implemented. However, potential risks may remain. Although adverse effects may be limited over time by the transient nature of mRNA electroporation, these safety mechanisms have been incorporated into mRNA sequences as an added safety control. Improved cell activation and trafficking toward the tumor site has also been achieved via co-electroporation of other RNAs that encode cytokines or chemokine receptors. Despite these advantages, current clinical evidence suggests that transient CAR- and TCR-based approaches have not yet reached the efficacy levels of more persistent gene-modified counterparts. This highlights the need for further optimization of treatment parameters such as dosing intensity and infusion scheduling. In addition, more complex treatment designs may be explored, including sequential administration strategies where a highly potent CAR product is used as an initial priming intervention, followed by repeated infusions of lower-potency constructs to sustain activity while mitigating toxicity. Acknowledgments This research was supported by a “Cellular Immunotherapy” grant from the vzw Baillet Latour Fund (Belgium) and the Cellular Therapy Fund from the Antwerp University Hospital (UZA) Foundation. F.V.O. was supported by his promotor Dr. Sébastien Anguille, who obtained an FWO Senior Clinical Investigator fellowship (1806225N). Z.K. holds a strategic basic research PHD fellowship from the Research Foundation – Flanders (FWO) (1S50925N). D.F. was funded by an Emmanuel van der Schueren starters grant from Stand Up To Cancer (KotK, Belgium; GRANT MULTPLEX), followed by a DOCPRO4 PhD grant of the Special Research Fund (BOF; GRANT MULTPLEX) of the University of Antwerp. E.L. was supported by the Methusalem Funding program from the University of Antwerp. D.C.D. is holder of a Junior postdoctoral fellowship from the Research Foundation – Flanders (FWO; grant 12B2W24N). Figures were created with BioRender.com. Author contributions D.C.-D. conceived this review. D.C.-D., Z.K., F.V.O., and D.F. reviewed the literature. D.C.-D. and DF. wrote the original manuscript. D.C.-D., Z.K., F.V.O., and D.F. edited the manuscript. E.L. contributed to the final version of the manuscript. Declaration of interests The authors declare no competing interests. Contributor Information Eva Lion, Email: eva.lion@uantwerpen.be. Diana Campillo-Davo, Email: diana.campillodavo@uantwerpen.be. References